Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Coherus BioSciences, Inc. (CHRS)
|
Add to portfolio |
|
|
|
| Price: |
$16.41
| | Metrics |
| OS: |
80.6
|
M
| |
|
|
| Market cap: |
$1.32
|
B
| |
-59
|
% ROIC
|
|
Net debt:
|
$327
|
M
| |
|
|
|
EV:
|
$1.65
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($240)
|
M
| |
|
|
|
EBIT
|
($234)
|
M
| |
|
|
| EPS |
($3.32)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 211.0 | 326.6 | 475.8 | 356.1 | 0.0 | 1.6 | 190.1 | 30.0 |
| Revenue growth | -35.4% | -31.4% | 33.6% | | -100.0% | -99.2% | 532.8% | -3.4% |
| Cost of goods sold | 70.1 | 57.6 | 37.7 | 17.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 141.0 | 269.0 | 438.2 | 339.0 | 0.0 | 1.6 | 190.1 | 30.0 |
| Gross margin | 66.8% | 82.4% | 92.1% | 95.2% | | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 198.5 | 169.7 | 139.1 | 137.0 | 94.2 | 71.3 | 51.6 | |
| Research and development | 199.4 | 363.1 | 142.8 | 94.2 | 110.2 | 162.4 | 254.4 | 213.1 |
| General and administrative | | | | | | | | 36.0 |
| EBIT | -256.9 | -263.9 | 156.3 | 107.8 | -204.4 | -232.1 | -115.9 | -219.1 |
| EBIT margin | -121.7% | -80.8% | 32.9% | 30.3% | | -14918.8% | -61.0% | -729.2% |
| Pre-tax income | -291.8 | -287.1 | 135.7 | 92.8 | -209.4 | -238.3 | -127.8 | -223.9 |
| Income taxes | 0.0 | 0.0 | 3.5 | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 2.6% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -291.8 | -287.1 | 132.2 | 89.8 | -209.3 | -238.2 | -127.3 | -223.3 |
| Net margin | -138.2% | -87.9% | 27.8% | 25.2% | | -15306.6% | -67.0% | -743.2% |
| |
| Diluted EPS | ($3.76) | ($3.81) | $1.58 | $1.23 | ($3.22) | ($4.48) | ($3.04) | ($6.01) |
| Shares outstanding (diluted) | 77.6 | 75.4 | 83.5 | 73.2 | 65.0 | 53.1 | 41.9 | 37.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|